September 15th 2025, 8:00pm
Dr. Geoffrey Liu discussed findings from the phase 2 TRUST-II clinical trial evaluating Ibtrozi (taletrectinib) among patients with ROS1-positive non-small cell lung cancer.
September 15th 2025, 1:00pm
Dr. Joshua Sabari spoke with advocate Chris Conneran on his journey from caregiver to champion for KRAS-mutant cancer patients and families.
September 13th 2025, 2:00pm
As the prostate cancer treatment landscape continues to evolve, understanding the risks and benefits of each approach is critical for patients.
September 12th 2025, 8:00pm
Dr. Josh Sabari and Max Doppelt explore challenges in trial enrollment and the potential of emerging therapies to offer hope for patients diagnosed today.
September 12th 2025, 7:00pm
This guide for newly diagnosed patients provides key information to help you understand your options and have informed conversations with your oncologist.
September 12th 2025, 4:00pm
Early-stage gynecologic cancer is confined to its original site and often treatable; diagnosis, surgery, and new therapies improve outcomes.
September 12th 2025, 1:00pm
Dr. Thomas Jankowski explained that THIO, a telomerase inhibitor, is being studied with Libtayo to help overcome resistance in advanced lung cancer.
September 11th 2025, 8:00pm
Advances are reshaping treatment for small cell lung cancer, with immunotherapy and emerging options offering hope for longer survival and potential cures.
September 10th 2025, 1:00pm
CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.
September 9th 2025, 1:00pm
CURE spoke with the patient advocate and author of “Between Two Kingdoms” and “The Book of Alchemy.”
Thanking My Support System From My Cancer Journey
Ibtrozi May Address Unmet Needs In ROS1-Positive Non-Small Cell Lung Cancer
Actively Recruiting Trials for Lung, Biliary, AML and Small Cell Cancer
The Lessons of the Woods